Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16090283 | 0.91 | CDK5 (0.54) | MAPTSMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL8480061 | 0.90 | PDE3B (0.68) | MAPTSMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL16090353 | 0.89 | MEN1 (0.59) | MAPTSMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL15682858 | 0.89 | AHR (0.54) | MAPTSMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL16090361 | 0.89 | MAPT (0.54) | MAPTSMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL16090359 | 0.89 | MAPT (0.53) | MAPTSMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL15682856 | 0.89 | MAPT (0.53) | MAPTSMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL16090328 | 0.87 | MAPT (0.49) | MAPTSMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL13028349 | 0.87 | CYP1A2 (0.68) | MAPTSMN1; SMN2POLBALDH1A1PDE3B | |
| SCHEMBL16137725 | 0.86 | POLB (0.66) | MAPTSMN1; SMN2POLBALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914575-B1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | UNIV MICHIGAN REGENTS (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2020061231-A1 | TREATMENT FOR OBESITY | 1GLOBE BIOMEDICAL CO., LTD. (CN) | 2020-03-26 | — | — | WO | disclosed |
| EP-3037419-B1 | COMPOSITIONS OF KINASE INHIBITORS AND THEIR USE FOR TREATMENT OF CANCER AND OTHER DISEASES RELATED TO KINASES | BOSTON BIOMEDICAL INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20180022743-A1 | COMPOSITIONS OF KINASE INHIBITORS AND THEIR USE FOR TREATMENT OF CANCER AND OTHER DISEASES RELATED TO KINASES | BOSTON BIOMEDICAL INC (US) | 2018-01-25 | — | — | US | disclosed |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | EASTERN MICHIGAN UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | EASTERN MICHIGAN UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-9725444-B2 | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | BOSTON BIOMEDICAL, INC (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725444-B2 | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | BOSTON BIOMEDICAL, INC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014070983-A1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20120321622-A1 | Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases | BOSTON BIOMEDICAL, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120321622-A1 | Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases | BOSTON BIOMEDICAL, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8299106-B2 | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | BOSTON BIOMEDICAL, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299106-B2 | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | BOSTON BIOMEDICAL, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100285006-A1 | Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases | BOSTON BIOMEDICAL, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100285006-A1 | Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases | BOSTON BIOMEDICAL, INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2009033033-A2 | COMPOSITIONS OF KINASE INHIBITORS AND THEIR USE FOR TREATMENT OF CANCER AND OTHER DISEASES RELATED TO KINASES | BOSTON BIOMEDICAL, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120321622-A1 | Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases | CILK1, MKNK1, MKNK2 | MAPT 1320/4885SMN1; SMN2 2225/4885POLB 2236/4885 |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | MAP3K1, MAP3K6, MAP3K9 | MAPT 3599/4885SMN1; SMN2 3337/4885POLB 1741/4885 |
| US-20100285006-A1 | Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases | CILK1, MKNK1, MKNK2 | MAPT 1320/4885SMN1; SMN2 2225/4885POLB 2236/4885 |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | MAPT 3634/4885SMN1; SMN2 3209/4885POLB 3185/4885 |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K2, MAP3K1, MAP3K3 | MAPT 3866/4885SMN1; SMN2 2581/4885POLB 2207/4885 |
| US-20180022743-A1 | COMPOSITIONS OF KINASE INHIBITORS AND THEIR USE FOR TREATMENT OF CANCER AND OTHER DISEASES RELATED TO KINASES | CILK1, MKNK1, MKNK2 | MAPT 1320/4885SMN1; SMN2 2225/4885POLB 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.